Whalesbook
Bharat mein Semaglutide Market mein Patent Expiry ke baad Halchal
Bharat mein semaglutide market mein patent ki expiry ke baad tezi se halchal mach gayi hai. 20 March, 2026 ko Novo Nordisk ka patent samapt hone ke baad, 40 se zyada deshi drug companies ne 50 se adhik generic versions launch kar diye hain. In generics ne daamon ko 90% tak gira diya hai. Kai generic version mahine mein sirf ₹1,290 mein mil rahe hain, jabki Novo ki Ozempic aur Wegovy ki pehle ki keemat ₹8,800 se ₹16,400 tak thi. Iske bawajood, Novo Nordisk India ke Managing Director Vikrant Shrotriya ne saaf kiya hai ki company in gehri discounts ko match nahi karegi. Iske bajay, Novo apni premium market share ko bachane ke liye apne vishal clinical data aur doctoron ke bharose par nirbhar karega.
Novo Nordisk ki Strategy: Data, Doctor, aur Partnerships
Novo Nordisk apni market position banaye rakhne ke liye apne drug ke mazboot clinical sabooton aur niyantrit access (controlled access) par zor de raha hai, daamon par pratispardha karne ke bajay. Company 50 se zyada clinical trials, lagbhag 10 saalon ke global use aur 4.9 crore patient years ke data ka hawala deti hai. Shrotriya ka manna hai ki yeh gehra saboot doctoron ka vishwas badhata hai. Zyadatar patients tak pahunchne ke liye, brand value kam kiye bina, Novo Nordisk ne December 2025 se apne injectable semaglutide ke daam 37% kam kiye hain. Company Abbott India aur Emcure ke saath milkar bhi distribution ko badha rahi hai, khaas kar chhote shaharon mein, taaki pehle se kam daamon par access mil sake. Yeh strategy Novo ke premium segment par kendrit hai, jo daam ki jung mein shamil hone ke bajay device ki quality aur lambe samay ke parinamon par zor deti hai.
Bharat ka Badhta GLP-1 Market aur Competitors ki Chal
Bharat mein GLP-1 drugs ka market, jo 2024 mein lagbhag $110.55 million (lagbhag ₹915 crore) ka tha, mein tezi se vikas hone ki ummeed hai. Yeh 2030 tak $350 million (lagbhag ₹2,900 crore) ko paar kar sakta hai, jiska mukhya karan diabetes aur obesity ki badhti dar hai. Bharat duniya bhar mein patent expiry ke baad ke halaton ko samajhne ke liye ek mahatvapurna udaharan ban gaya hai. Jabki 40 se zyada companies ne generic semaglutide launch kiya hai, prati spardhak alag-alag takneek apna rahe hain. Natco Pharma sasti vials ke saath high volume ka lakshya rakhti hai, jabki Sun Pharma aur Dr. Reddy's Novo se kam daamon par istemal mein aasan pen devices pesh kar rahe hain. Torrent Pharma oral versions bhi develop kar rahi hai. Generic dawaen sasti hain, lekin unhein complex manufacturing, cold chain aur doctor training jaise chunautiyon ka samna karna padta hai, jinmein Novo Nordisk ko fayda hai. Analysts ka anuman hai ki market simat jayegi aur kuch bade brands aage rahenge. Novo Nordisk ka P/E ratio lagbhag 10.5 hai, jo market average 43.79 se kaafi kam hai. Yeh investors ki pricing power ko lekar chinta ka sanket ho sakta hai, bhale hi company ka itihas mazboot ho aur anya bade markets mein 2032 tak patent suraksha ho.
Novo Nordisk ke Liye Jokhim: Margin Pressure aur Market Share Loss
Apne clinical strength par zor dene ke bawajood, Novo Nordisk ko bade jokhim ka samna karna pad raha hai. Bhartiya generics itni aggressive prices (90% tak discount) par launch ki gayi hain ki yeh Novo ke profit margins ko khatre mein daal sakti hain aur sales volume mein badi kami la sakti hain. Abbott India aur Emcure jaise partners par nirbhar hona, jo ki zaroori hai, company par nirbharata badhata hai aur profit margins ko kam kar sakta hai. India mein semaglutide ka tezi se commoditization (samanyikaran) duniya bhar mein kam pricing expectations ko set kar sakta hai. Regulatory issues, jaise GLP-1 ki safety reporting par pehle ki FDA warnings, bhi jokhim badhate hain. Jabki Novo Nordisk ke paas anya deshon mein mazboot patents hain, India mein generics ka tezi se apnana ise tough competition aur khoi hui pricing power ke prati kamzor dikhata hai. Company vafadar doctoron aur premium patients ka ek varg banae rakh sakti hai, lekin Bharat ke price-sensitive, high-volume market mein overall market share kho sakti hai.
Market Growth Potential aur Analysts Views
Bharat ka semaglutide market agle paanch saalon mein lagbhag ₹1,600 crore se ₹12,000 crore tak pahunchne ki ummeed hai. Yeh vistar Bharat mein diabetes aur obesity se pidit logon ki badi sankhya aur GLP-1 drugs tak behtar pahunch ke karan ho raha hai. Apni mazboot clinical pratishtha aur targeted market approach par kayam rahkar, Novo Nordisk ek mahatvapurna player bana rah sakta hai, bhale hi woh generics ko kuch sales volume kho de. Analysts ke Novo Nordisk par mile-jule vichar hain, 'Hold' rating aur $43.00 se $65.56 ke beech average price targets hain. Yeh company ki mazbootiyon aur naye prati spardha ke chunautiyon dono ko darshata hai. Novo Nordisk ki safalta is baat par nirbhar karegi ki woh is badalte mahol mein apne premium market share ko banaye rakhne ke liye apne clinical data aur partnerships ka kitna achha istemal karta hai.